Rilmenidine
Rilmenidine is a selective imidazoline I1 receptor agonist and alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system by acting on imidazoline receptors in the rostral ventrolateral medulla and nucleus tractus solitarius, thereby decreasing peripheral vascular resistance and heart rate. It is used for the treatment of hypertension with a more favorable side effect profile than older central antihypertensives.
Peso molecular
180,2500 g/mol
LogP
1,20
TPSA
33,60 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C1COC(NC(C2CC2)C2CC2)=N1
InChI
InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
Molecular Formula
C10H16N2O
HBD / HBA
1 / 2
Enlaces Rotables
4
Átomos Pesados
13
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Rilmenidine is a selective imidazoline I1 receptor agonist and alpha-2 adrenergic agonist that reduces sympathetic outflow from the central nervous system by acting on imidazoline receptors in the rostral ventrolateral medulla and nucleus tractus solitarius, thereby decreasing peripheral vascular resistance and heart rate. It is used for the treatment of hypertension with a more favorable side effect profile than older central antihypertensives.
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.
Yes, Rilmenidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL289480. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68712. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rilmenidine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rilmenidine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rilmenidine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rilmenidine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rilmenidine"></drugfyi-drug>